Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Multiple Myeloma

Multiple Myeloma

Part of Plasma cell dyscrasias

33 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Multiple Myeloma

590 trials tracked for Multiple Myeloma: 93 in phase 3 or 4 and 40 with published results. The most-cited published study has 1325 citations.

590Trials tracked
93Phase 3 & 4
0Recruiting
40With published results
Phase distribution
Phase 4 8 Phase 3 85 Phase 2 397 Phase 1 51 Other / NA 49
  1. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma Completed · 1,325 cited
  2. Phase 3 A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Completed · 957 cited
  3. Phase 3 Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma Completed · 441 cited
  4. Phase 3 Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma. Completed · 423 cited
  5. Phase 3 A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy Completed · 407 cited
  6. Phase 3 Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 385 cited
Show 44 more trials
  1. Phase 3 Multinational Clinical Study Comparing Isatuximab, Carfilzomib And Dexamethasone To Carfilzomib And Dexamethasone In Relapse And/Or Refractory Multiple Myeloma Patients Completed · 381 cited
  2. Phase 3 Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement Completed · 359 cited
  3. Phase 3 Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex Completed · 327 cited
  4. Phase 3 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) Completed · 277 cited
  5. Phase 3 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma Completed · 271 cited
  6. Phase 3 Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Completed · 260 cited
  7. Phase 3 Baclofen-Amitriptyline Hydrochloride-Ketamine Gel in Treating Peripheral Neuropathy Caused by Chemotherapy in Patients With Cancer Completed · 255 cited
  8. Phase 3 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant Completed · 236 cited
  9. Phase 3 Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN) Completed · 227 cited
  10. Phase 3 Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Completed · 207 cited
  11. Phase 3 Evaluation of Safety of Pomalidomide in Combination With Dexamethasone (Low Dose) in Patients With Refractory or Relapsed and Refractory Multiple Myeloma Completed · 162 cited
  12. Phase 3 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed · 155 cited
  13. Phase 3 Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma Completed · 144 cited
  14. Phase 3 A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma Completed · 141 cited
  15. Phase 3 A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Completed · 130 cited
  16. Phase 3 Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma Completed · 130 cited
  17. Phase 3 Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma Completed · 120 cited
  18. Phase 3 A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy Completed · 114 cited
  19. Phase 3 Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant Completed · 112 cited
  20. Phase 3 A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma Completed · 102 cited
  21. Phase 3 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma Completed · 99 cited
  22. Phase 3 A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) Completed · 79 cited
  23. Phase 3 A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma Completed · 52 cited
  24. Phase 4 Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants Completed · 51 cited
  25. Phase 3 Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma Completed · 47 cited
  26. Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma Completed · 45 cited
  27. Phase 3 Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma Completed · 31 cited
  28. Phase 3 Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients Completed · 31 cited
  29. Phase 3 Velcade (Bortezomib) Consolidation After Transplant Completed · 17 cited
  30. Phase 4 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Completed · 15 cited
  31. Phase 3 A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma Completed · 11 cited
  32. Phase 3 Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention Completed · 11 cited
  33. Phase 3 Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Completed · 11 cited
  34. Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed · 2 cited
  35. Phase 4 Lenalidomide and Dexamethasone With/Without Stem Cell Transplant in Patients With Multiple Myeloma Completed
  36. Phase 4 Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma Completed
  37. Phase 4 Home Based Daratumumab Administration for Patients With Multiple Myeloma Completed
  38. Phase 4 A Multiple Myeloma Trial in Patients With Bone Metastases Completed
  39. Phase 4 Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) Completed
  40. Phase 3 A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple Myeloma Completed
  41. Phase 3 A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma Completed
  42. Phase 3 Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma Completed
  43. Phase 3 Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) Completed
  44. Phase 3 Aplidin - Dexamethasone in Relapsed/Refractory Myeloma Completed

Showing the 50 most-cited and recently-updated of 590 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Multiple Myeloma: what the trials found

Daratumumab treatment showed significant improvements in Minimal Residual Disease (MRD) Negativity Rates during both primary analysis (35.4% vs. 53.3%, p=0.0004) 1 and final progression-free survival (PFS) analysis (39.4% vs. 60.9%, p=<0.0001) 1. In a separate study, Daratumumab was evaluated in patients with symptomatic multiple myeloma, where the percentage of participants achieving a partial response or better (sCR + CR + VGPR + PR) was reported as 56.1%, 56.1%, and 37.5% across different cohorts 5.

Ixazomib demonstrated a 12-month PFS rate of 50.0%, 48.7%, and 48.9% in patients, with 33.3%, 43.6%, and 42.2% achieving VGPR or better 17. Additionally, Ixazomib was shown to achieve a best response rate of 33.3%, 23.1%, 24.4%, 0%, 20.5%, and 17.8% across various groups 17.

Zoledronic acid was evaluated for skeletal-related events (SRE) at one year, showing rates of 0% and 0.17% 15, with pathologic bone fracture rates of 0.00%, 0.07%, 0.00%, and 0.03% 15. Furthermore, the incidence of spinal cord compression was 0.00%, 0.07%, 0.00%, and 0.00% 15. In a separate study on zoledronic acid, the number of participants with a significant increase in serum creatinine at 12 months was 17 and 13, while at 24 months, it was 24 and 23 22.

Lenalidomide was evaluated in a cohort where 34% of patients achieved an upgrade in response based on their best disease response 11. In another study, the efficacy of BCMA CAR-T Cell Therapy using Lenalidomide showed a significant difference (25% vs. 13%, p=<0.0001) 11.

Treatment with Daratumumab and Hyaluronidase-fihj resulted in high treatment satisfaction scores via the SWT score from the Cancer Treatment Satisfaction Questionnaire (CTSQ) across cycles 1, 2, and 3 (87.2%, 87.4%, and 89.3% respectively) 18.

Recent results — preliminary, needs further review

  • Siltuximab 2
  • Pomalidomide 3
  • Fludarabine 6
  • Bortezomib 8
  • Evomela 9

For the clinician treating this condition

  • Daratumumab is associated with significant improvements in Minimal Residual Disease (MRD) Negativity rates compared to standard controls 1.
  • Ixazomib shows consistent progression-free survival and high response rates (VGPR or better) in clinical settings 17.
  • Zoledronic acid demonstrates low rates of skeletal-related events and spinal cord compression, with manageable impacts on serum creatinine over 24 months [15, 22].

AI synthesis of 12 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration
Oncology RCT
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration Trial compares continuous versus fixed duration lenalidomide for myeloma
This Phase 3 randomized trial of 516 patients with standard-risk newly diagnosed multiple myeloma found that indefinite-duration lenalidomid…
A large trial found that continuing lenalidomide treatment indefinitely did not improve overall survival compared to a fixed two-year plan.
Jul 18, 2026
VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7
Oncology Meta-analysis
VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7 Current risk tools for blood clots in multiple myeloma patients do not work well enough for doctors to trust
This systematic review and meta-analysis of 14 studies evaluated VTE risk prediction models in multiple myeloma. Pooled VTE incidence was 7.…
A review of fourteen studies found that existing models fail to accurately predict blood clots in multiple myeloma patients. The tools used …
Jun 1, 2026
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Hematology Sys. Review
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Frontiers May 23, 2026
Systematic review and meta-analysis of BCMA or GPRC5D bispecific antibodies in relapsed refractory multiple myeloma
Orthopedics & Sports Medicine Meta-analysis
Systematic review and meta-analysis of BCMA or GPRC5D bispecific antibodies in relapsed refractory multiple myeloma New antibodies help some myeloma patients live longer, but infection risks are high
This systematic review and meta-analysis evaluates BCMA- or GPRC5D-directed CD3 bispecific antibodies in 1,900 patients with relapsed or ref…
A review of 1,900 patients found new antibodies helped many with advanced myeloma, yet serious infections and low white blood cell counts re…
Frontiers May 21, 2026
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
Oncology FDA Approval
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
FDA May 5, 2026
Narrative review explores natural products targeting proteasome in multiple myeloma
Drug Pipeline Sys. Review
Narrative review explores natural products targeting proteasome in multiple myeloma Natural Products May Help Beat Cancer Drug Resistance
This narrative review summarizes literature up to 2025 on natural products that directly target the proteasome or enhance sensitivity to pro…
New natural compounds may help overcome resistance to powerful cancer drugs, offering hope for patients who stop responding to treatment.
Frontiers May 4, 2026
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
Oncology FDA Approval
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA May 2, 2026
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
Oncology FDA Approval
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…
FDA May 2, 2026
Meta-analysis compares infection rates of teclistamab in clinical trials and real-world evidence
Allergy & Immunology Meta-analysis
Meta-analysis compares infection rates of teclistamab in clinical trials and real-world evidence Teclistamab linked to higher infection rates in some patients
This meta-analysis of 714 patients evaluates the incidence of infections in relapsed/refractory multiple myeloma treated with teclistamab.
New data shows that patients using teclistamab for multiple myeloma may face a significant risk of developing various types of infections.
Frontiers Apr 30, 2026
Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates
Oncology Meta-analysis
Meta-analysis of CD38-directed CAR-T therapy in relapsed refractory multiple myeloma reports high response rates New CD38 CAR-T therapy shows high success rates for late-stage multiple myeloma patients
This systematic review and meta-analysis evaluated CD38-directed CAR-T cell therapy in patients with relapsed refractory multiple myeloma.
A new immune therapy targeting CD38 and BCMA offers deep remission for late-stage multiple myeloma patients while managing side effects like…
Frontiers Apr 29, 2026
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Oncology Sys. Review
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Frontiers Apr 28, 2026
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma
Oncology
Qualitative review of tocilizumab use with bispecific antibodies in relapsed/refractory multiple myeloma New drugs for myeloma need a safety net to work well
This qualitative interview review synthesizes perspectives from ten hematologists/oncologists regarding bispecific antibody (BsAb) use in…
New powerful drugs treat myeloma better, but patients need a safety net to handle side effects and stay on track for a long time.
medRxiv Apr 27, 2026

Research across Plasma cell dyscrasias

Related studies from across the Plasma cell dyscrasias family.

Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation
Allergy & Immunology Sys. Review
Early daratumumab or immunomodulatory agents in high-risk smoldering multiple myeloma show uncertain benefits versus observation Early Drug May Delay Multiple Myeloma
This systematic review evaluated early intervention with monoclonal antibodies, immunomodulatory agents, or alkylating agents versus observa…
Imagine waking up with a headache. You take a pill, and the pain goes away.
Cochrane Apr 10, 2026

Questions about Multiple Myeloma

Can linvoseltamab improve outcomes for patients with relapsed/refractory multiple myeloma compared to standard care?

Linvoseltamab may improve outcomes for relapsed/refractory multiple myeloma, with a 2025 indirect comparison showing longer survival and higher response rates than teclistamab, a similar bispecific antibody.

Full answer →
Does teclistamab cause infections in patients with relapsed/refractory multiple myeloma based on real-world data?

Yes, real-world data shows teclistamab causes infections in about 45% of patients, with severe infections in about 23%, which is lower than clinical trial rates.

Full answer →
What is the response rate for talquetamab and teclistamab combination in relapsed/refractory multiple myeloma?

The talquetamab and teclistamab combination shows a 79% overall response rate in relapsed/refractory multiple myeloma with extramedullary disease, based on the phase 2 RedirecTT-1 study.

Full answer →
What are the infection rates for patients with relapsed/refractory multiple myeloma taking teclistamab?

In relapsed/refractory multiple myeloma patients taking teclistamab, about 57% experience any infection and about 28% have a severe (grade ≥3) infection, based on a meta-analysis.

Full answer →
Do hematologists recommend using tocilizumab with bispecific antibodies for relapsed Multiple Myeloma?

Yes, hematologists recommend using tocilizumab to manage cytokine release syndrome (CRS) caused by bispecific antibodies in relapsed/refractory multiple myeloma, including prophylactic use in outpatient settings.

Full answer →
What treatments were used in the case report for ultra-high-risk relapsed Multiple Myeloma?

The case report used a combination of ixazomib, lisaftoclax, and dexamethasone (ILD) as maintenance therapy after CAR-T cell therapy for ultra-high-risk relapsed multiple myeloma.

Full answer →
Can Pomalyst be used to treat Kaposi sarcoma in addition to Multiple Myeloma?

Yes, Pomalyst is FDA-approved for both multiple myeloma and Kaposi sarcoma, including AIDS-related and HIV-negative cases.

Full answer →
Is Revlimid approved for maintenance therapy after an autologous stem cell transplant for Multiple Myeloma?

Yes, Revlimid (lenalidomide) is FDA-approved as maintenance therapy after autologous stem cell transplant for multiple myeloma.

Full answer →
See all 10 questions about Multiple Myeloma →

All Multiple Myeloma Articles